This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Satsuma Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth €317.23K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Informations clés
John Kollins
Directeur général
US$1.9m
Rémunération totale
| Pourcentage du salaire du PDG | 27.8% |
| Durée du mandat du directeur général | 6.9yrs |
| Propriété du PDG | 0.9% |
| Durée moyenne d'occupation des postes de direction | 5.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.8yrs |
Mises à jour récentes de la gestion
Recent updates
Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$2m | US$530k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$830k | US$500k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$456k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$391k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$568k | US$362k | -US$7m |
Rémunération vs marché: John's total compensation ($USD1.91M) is above average for companies of similar size in the German market ($USD407.72K).
Rémunération et revenus: John's compensation has increased whilst the company is unprofitable.
PDG
John Kollins (60 yo)
6.9yrs
Titularisation
US$1,909,812
Compensation
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% € 14.2k | |
| VP & Head of Operations | 6.4yrs | pas de données | pas de données | |
| Senior VP & Head of Chemistry | 5.9yrs | pas de données | pas de données | |
| VP & Head of Regulatory Affairs | 5.1yrs | pas de données | pas de données |
5.9yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Gestion expérimentée: 1LV's management team is seasoned and experienced (5.9 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Independent Director | 2.9yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.8yrs | US$131.58k | 0% € 0 | |
| Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% € 0 | |
| Independent Director | 6.5yrs | US$120.58k | 0% € 0 | |
| Independent Director | 1.7yrs | US$124.58k | 0% € 0 | |
| Independent Director | 7yrs | US$124.08k | 0% € 0 | |
| Independent Director | 4.1yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.7yrs | US$126.08k | 0% € 0 |
5.8yrs
Durée moyenne de l'emploi
59yo
Âge moyen
Conseil d'administration expérimenté: 1LV's board of directors are considered experienced (5.8 years average tenure).